ImmTAC/Anti‐PD‐1 antibody combination to enhance killing of cancer cells by reversing regulatory T‐cell‐mediated immunosuppression

Recently, bi‐functional molecules that can redirect immune effectors to tumour cells have emerged as potentially robust mediators of tumour regression in clinical trials. Two modalities in particular, bi‐specific antibodies for T‐cell redirection and activation (BiTe) and immune‐mobilizing monoclona...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Immunology
Glavni autori: Zhang, Huanling, Li, Yanyan, Liu, Xiaoping, Liang, Zhaoduan, Yan, Mengyong, Liu, Qiang, Chen, Anan, Bao, Yifeng, Zhou, Chengzhi, Li, Shiyue, Yee, Cassian, Li, Yi
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6142295/
https://ncbi.nlm.nih.gov/pubmed/29791021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/imm.12954
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items